Drug-related thrombosis in hematologic malignancies

Reviews in Clinical and Experimental Hematology

Volumn 8, Issue 1, 2004, Pages

  Nadir, Yona ^a   Hoffman, Ron ^a   Brenner, Benjamin ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BLEOMYCIN; BORTEZOMIB; CISPLATIN; COLONY STIMULATING FACTOR 1; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ENOXAPARIN; ERWINIA ASPARAGINASE; ERYTHROPOIETIN; ESCHERICHIA COLI ASPARAGINASE; ETOPOSIDE; FRESH FROZEN PLASMA; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PREDNISONE; PROCOAGULANT; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; BLOOD CLOTTING DISORDER; BONE MARROW TOXICITY; CLINICAL TRIAL; CRYOPRECIPITATE; DIABETES MELLITUS; ENDOTHELIUM LESION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MYELOMA; PANCREATITIS; PLASMA TRANSFUSION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM;

EID: 21744456207     PISSN: 11270020     EISSN: 1825151X     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Falanga A and Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost, 25: 173-82, 1999.
2. Tallal L, Tan C, Oettgen H et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer, 25: 306-20, 1970.
3. Dellinger CT and Miale TD. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer, 38: 1843-6, 1976.
4. Sahu S, Saika S, Pai SK et al. L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol, 15: 533-8, 1998.
5. Pui CH, Burghen GA, Bowman WP et al. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr, 99: 46-50, 1981.
6. Priest JR, Ramsay NK, Bennett AJ et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr, 100: 984-9, 1989.
7. Mitchell LG, Sutor AH and Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost, 21: 390-401, 1995.
8. Kieslich M, Porto L, Lanfermann H et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol, 25: 484-7, 2003.
9. Alberts SR, Bretscher M, Wiltsie JC et al. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leuk Lymphoma, 32: 489-96, 1999.
10. Elhasid R, Lanir N, Sharon R et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis, 12: 367-70, 2001.
11. Nowak-Gottl U, Heinecke A, von Kries R et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res, 103: 165-72, 2001.
12. Hongo T, Okada S, Ohzeki T et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int, 44: 293-9, 2002.
13. Mitchell LG, Andrew M, Hanna K et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer, 97: 508-16, 2003.
14. Liebman HA, Wada JK, Patch MJ et al. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer, 50: 451-6, 1982.
15. Bezeaud A, Drouet L, Leverger G et al. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr, 108: 698-701, 1986.
16. Vigano'D'Angelo S, Gugliotta L, Mattioli Belmonte M et al. L-asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent carboxylation. Thromb Res, 59: 985-94, 1990.
17. Homans AC, Rybak ME, Baglini RL et al. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol, 5: 811-7, 1987.
18. Semeraro N, Montemurro P, Giordano P et al. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia. Thromb Haemost, 64: 38-40, 1990.
19. Jaime-Perez JC and Gomez-Almaguer D. Platelet aggregation is stimulated by L-asparginase in children with acute lymphoblastic leukemia and normal individuals. Haematologica, 87: 891-2, 2002.
20. Nowak-Gottl U, Werber G, Ziemann D et al. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica, 81: 127-31, 1996.
21. Mall V, Thomas KB, Sauter S et al. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr. 211: 205-10, 1999.
22. Duval M, Suciu S, Ferster A et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood, 99: 2734-9, 2002. (full text)
23. Nowak-Gottl U, Rath B, Binder M et al. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica, 80: 451-3, 1995.
24. Halton JM, Mitchell LG, Vegh P et al. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol, 47: 157-61, 1994.
25. Nowak-Gottl U, Kuhn N, Wolff JE et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol, 56: 35-8, 1996.
26. Gugliotta L, D'Angelo A, Mattioli Belmonte M et al. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol, 74: 465-70, 1990.
27. Mazzucconi MG, Gugliotta L, Leone G et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Blood Coagul Fibrinolysis, 5: 23-8, 1994.
28. Mitchell L, Andrew M, Hanna K et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost, 90: 235-44, 2003.
29. Vacca A, Ria R, Semeraro F et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood, 102: 3340-8, 2003. (full text)
30. Haslett PA, Hanekom WA, Muller G et al. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis, 187: 946-55, 2003. (full text)
31. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98: 492-4, 2001.
32. Steins MB, Bieker R, Padro T et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol, 123: 436-41, 2003.
33. Raza A, Meyer P, Dutt D et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 98: 958-65, 2001. (full text)
34. Mesa RA, Steensma DP, Pardanani A et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 101: 2534-41, 2003. (full text)
35. Piette JC, Sbai A and Frances C. Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus, 11: 67-70, 2002.
36. Desai AA, Vogelzang NJ, Rini BI et al. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer, 95: 1629-36, 2002.
37. Horne MK 3rd, Figg WD, Arlen P et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy, 23: 315-8, 2003.
38. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93: 55-65, 1999. (full text)
39. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 98: 1614-5, 2001. (full text)
40. Weber D, Ginsberg C, Walker P et al. Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide- dexamethasone (TD) (abstract). Blood, 100: 787, 2002.
41. Rajkumar SV, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia, 17: 775-9, 2003. (full text)
42. Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica. 87: 408-14, 2002.
43. Cavo M, Zamagni E, Cellini C et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood, 100: 2272-3, 2002. (full text)
44. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol, 20: 4319-23, 2002. (full text)
45. Osman K, Comenzo R and Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med, 344: 1951-2, 2001.
46. Zervas K, Dimopoulos MA, Hatzicharissi E et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol, 15: 134-8, 2004. (full text)
47. Anagnostopoulos A, Weber D, Rankin K et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol, 121: 768-71, 2003.
48. Camba L, Peccatori J, Pescarollo A et al. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica, 86: 1108-9, 2001. (full text)
49. Kropff MH, Lang N, Bisping G et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol, 122: 607-16, 2003.
50. Urbauer E, Kaufmann H, Nosslinger T et al. Thromboembolic events during treatment with thalidomide. Blood, 99: 4247-8, 2002. (full text)
51. Moehler TM, Neben K, Benner A et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood, 98: 3846-8, 2001. (full text)
52. Zangari M, Siegel E, Barlogie B et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood, 100: 1168-71, 2002. (full text)
53. Haim N, Lanir N, Hoffman R, Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med, 110: 91-6, 2000.
54. Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis, 13: 187-92, 2002.
55. Minnema MC, Fijnheer R, De Groot PG et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 1: 445-9, 2003.
56. Kaushal V, Kaushal GP, Melkaveri SN et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost, 2: 327-34, 2004.
57. Zangari M, Barlogie B, Saghafifar F et al. Effect of anticoagulation on development and recurrence of deep vein thrombosis (DVT) in multiple myeloma patients treated with chemotherapy and thalidomide (Total therapy II) (abstract). Hematol J, 4(suppl 1): 358, 2003.
58. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol, 163: 380-6, 1999. (full text)
59. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100: 3063-7, 2002. (full text)
60. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348: 2609-17, 2003.
61. Barbui T, Finazzi G, Grassi A et al. Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost, 75: 368-71, 1996.
62. Canales MA, Arrieta R, Gomez-Rioja R et al. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J Hematother Stem Cell Res, 11: 675-81, 2002.
63. LeBlanc R, Roy J, Demers C et al. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant, 23: 991-6, 1999.
64. Furihata M, Sonobe H, Iwata J et al. Lung squamous cell carcinoma producing both parathyroid hormone-related peptide and granulocyte colony stimulating factor. Pathol Int, 46: 376-9, 1996.
65. Conti JA and Scher HI. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity. Cancer, 70: 2699-702, 1992.
66. Falanga A, Marchetti M, Evangelista V at al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood, 93: 2506-14, 1999.
67. Stasko J, Drouet L, Soria C et al. Erythropoietin and granulocyte colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture. Thromb Res, 105: 161-4, 2002.
68. Kuroiwa M, Okamura T, Kanaji T et al. Effects of granulocyte colony-stimulating factor on the hemostatic system in healthy volunteers. Int J Hematol, 63: 311-6, 1996.
69. Kawachi Y, Watanabe A, Uchida T et al. Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor. Br J Haematol, 94: 413-6, 1996.
70. Shimoda K, Okamura S, Harada N et al. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest, 91: 1310-3, 1993. (full text)
71. Gozdasoglu S, Unal E, Yavuz G et al. Granulocyte-macrophage colony stimulating factor (rh-GM-CSF) in the treatment of chemotherapy-induced neutropenia. J Chemother, 7: 467-9, 1995.
72. Ho AD, Del Valle F, Engelhard M et al. Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study. Cancer, 66: 423-30, 1990.
73. Nissen C, Tichelli A, Gratwohl A et al. Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia patients with very severe neutropenia. Blood, 72: 2045-7, 1988.
74. O'Reilly SE, Gelmon KA, Onetto N et al. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. J Clin Oncol, 11: 2411-6, 1993.
75. Hotton KM, Khorsand M, Hank JA et al. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer, 88: 1892-901, 2000.
76. Tolcher AW, Giusti RM, O'Shaughnessy JA et al. Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases. Cancer Invest, 13: 188-92, 1995.
77. Zuckerman SH, Suprenant YM et al. Induction of endothelial cell/macrophage procoagulant activity: synergistic stimulation by gamma interferon and granulocyte-macrophage colony stimulating factor. Thromb Haemost, 61: 178-82, 1989.
78. Casati S, Passerini P, Campise MR et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J (Clin Res Ed), 295: 1017-20, 1987.
79. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med, 111: 992-1000, 1989.
80. Kaupke CJ, Butler GC and Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol, 3: 1672-9, 1993.
81. Standage BA, Schuman ES, Ackerman D et al. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates? Am J Surg, 165: 650-4, 1993.
82. Wun T, Law L, Harvey D et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer, 98: 1514-20, 2003.
83. Rose EH, Abels RI, Nelson RA et al. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol, 89: 831-7, 1995.
84. Steurer M, Sudmeier I, Stauder R et al. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol, 121: 101-3, 2003.
85. Nagel RL, Vichinsky E, Shah M et al. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood, 81: 9-14, 1993. (full text)
86. Malyszko JS, Malyszko J, Pawlak K et al. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin. Nephron, 84: 305-11, 2000.
87. Taylor JE, Henderson IS, Stewart WK et al. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet, 338: 1361-2, 1991.
88. Elliott MA, Nichols WL Jr, Plumhoff EA et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc, 78: 421-30, 2003.
89. Pettitt AR and Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant, 14: 495-504, 1994.
90. Tezcan H, Zimmer W, Fenstermaker R et al. Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506. Bone Marrow Transplant, 21: 105-9, 1998.
91. Ruutu T, Hermans J, Niederwieser D et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol, 118: 1112-9, 2002.
92. Atkinson K, Biggs JC, Hayes J et al. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol, 54: 59-67, 1983.
93. Zent R, Katz A, Quaggin S et al. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A. Clin Nephrol, 47: 181-6, 1997.
94. Teshima T, Miyoshi T, Ono M et al. Cyclosporine-related encephalopathy following allogeneic bone marrow transplantation. Int J Hematol, 63: 161-4, 1996.
95. Zoja C, Furci L, Ghilardi F et al. Cyclosporin-induced endothelial cell injury. Lab Invest, 55: 455-62, 1986.
96. Fogo A, Hakim RC, Sugiura M et al. Severe endothelial injury in a renal transplant patient receiving cyclosporine. Transplantation, 49: 1190-2, 1990.
97. Burke GW, Ciancio G, Cirocco R et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. Transplantation, 68: 1336-42, 1999.
98. Grace AA, Barradas MA, Mikhailidis DP et al. Cyclosporine A enhances platelet aggregation. Kidney Int, 32: 889-95, 1987.
99. Teruya J, Styler M, Verde S et al. Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation. J Clin Apheresis, 16: 169-74, 2001.
100. Corti P, Uderzo C, Tagliabue A et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant, 29: 542-3, 2002.
101. Alessandrino EP, Martinelli G, Canevari A et al. Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura. Bone Marrow Transplant, 25: 1217-8, 2000.
102. Lesesne JB, Rothschild N, Erickson B et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol, 7: 781-9, 1989.
103. Jackson AM, Rose BD, Graff LG et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med, 101: 41-4, 1984.
104. Fields SM and Lindley CM. Thrombotic microangiopathy associated with chemotherapy: case report and review of the literature. DICP, 23: 582-8, 1989.
105. Thurnher D, Kletzmayr J, Formanek M et al. Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology, 61: 143-6, 2001.
106. Gradishar WJ, Vokes EE, Ni K et al. Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report. Cancer, 66: 1914-8, 1990.
107. Angiola G, Bloss JD, DiSaia PJ et al. Hemolytic-uremic syndrome associated with neoadjuvant chemotherapy in the treatment of advanced cervical cancer. Gynecol Oncol, 39: 214-7, 1990.
108. Watson PR, Guthrie TH Jr and Caruana RJ. Cisplatin-associated hemolytic-uremic syndrome. Successful treatment with a staphylococcal protein A column. Cancer, 64: 1400-3, 1989.
109. Canpolat C, Pearson P and Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer, 74: 3059-62, 1994.
110. Walter RB, Joerger M and Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis, 40: E16, 2002.
111. Kohn S, Fradis M, Podoshin L et al. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Patho, l 21: 289-99, 1997.
112. Licciardello JT, Moake JL, Rudy CK et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology, 42: 296-300, 1985.
113. Palmisano J, Agraharkar M and Kaplan AA. Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange. Am J Kidney Dis, 32: 314-7, 1998.
114. Sartori TM, Maurizio PG, Sara P et al. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. J Heart Lung Transplant, 18: 693-700, 1999.
115. Ozturk G, Ozsoylu S and Gursel T. Effects of methylprednisolone on FVIII:C and vWF levels. Eur J Haematol, 53: 119-20, 1994.